Published in Medical Letter on the CDC and FDA, April 26th, 2006
"As a relationship between nelfinavir antiretroviral efficacy and plasma concentrations has been previously established, nelfinavir pharmacokinetics" were evaluated in a recent study from France, "in order to optimize the individual treatment schedule in a pediatric population."
"A population pharmacokinetic model was developed to describe the concentration-time course of nelfinavir and its active metabolite M8," explained D. Hirt and coauthors working at H˘pital Saint Vincent de Paul in Paris. "Individual characteristics were used to explain the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA